Enhertu completes its front-line march
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
Ziihera bags a gastric win
But Enhertu is coming.
The month ahead: November’s upcoming events
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
ESMO 2025 – Enhertu’s perioperative Destiny beckons
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
ESMO 2025 – Boehringer and Bayer eye the front line
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
Grit enters the in vivo Car-T race
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
